Kbi-110 !!top!! May 2026

| Patent | Territory | Expiry | Notes | |---|---|---|---| | (Composition of matter) | US, Canada, EU | 2035 | Covers the chiral cyclopropyl stereochemistry | | WO 2023/118456 (Method of treatment – psoriasis) | Worldwide | 2033 | Broad claim on JAK1‑selective inhibition | | US 11,001,214 (Formulation – immediate‑release tablet) | US | 2032 | Enables generic‑type QD dosing | | Pending (Biomarker‑guided dosing) | US/EU/JP | 2038 (estimated) | Expected filing Q3 2026 |